Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells

被引:75
作者
Folini, M [1 ]
Brambilla, C [1 ]
Villa, R [1 ]
Gandellini, P [1 ]
Vignati, S [1 ]
Paduano, F [1 ]
Daidone, MG [1 ]
Zaffaroni, N [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy
关键词
telomerase; hTERT; hTERC; apoptosis; prostate cancer;
D O I
10.1016/j.ejca.2004.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Recent evidence points to a novel function of human telomerase reverse transcriptase (hTERT) in promoting tumour cell survival, which might be independent of the telomere-elongating activity of the enzyme. To test this hypothesis, we evaluated comparatively the effects of telomerase inhibition, accomplished through antisense oligonucleotide-mediated interference with hTERT or human telomerase RNA component (hTERC), on the proliferative potential of DU145 human prostate cancer cells. Exposure of cells to a 2'-O-methyl-RNA phosphorothioate oligonucleotide targeting a splicing site within hTERT pre-mRNA induced almost complete inhibition of telomerase activity as a consequence of a marked reduction of the hTERT mRNA expression level, an early decline of DU145 cell growth and apoptotic cell death without any appreciable telomere shortening. Conversely, exposure of DU145 cells to a 2'-O-methyl-RNA phosphorothioate oligonucleotide targeting the template region of hTERC failed to interfere with cell proliferation in spite of the almost complete abrogation of telomerase activity. These results extend and corroborate earlier evidence in favour of an enzymatic activity-independent mechanism by which hTERT maintains tumour cell survival and proliferation. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:624 / 634
页数:11
相关论文
共 39 条
[1]
Telomerase as a possible target for anticancer therapy [J].
Autexier, C .
CHEMISTRY & BIOLOGY, 1999, 6 (11) :R299-R303
[2]
Avilion AA, 1996, CANCER RES, V56, P645
[3]
Telomere states and cell fates [J].
Blackburn, EH .
NATURE, 2000, 408 (6808) :53-56
[4]
STRUCTURE AND FUNCTION OF TELOMERES [J].
BLACKBURN, EH .
NATURE, 1991, 350 (6319) :569-573
[5]
Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells [J].
Brambilla, C ;
Folini, M ;
Gandellini, P ;
Daprai, L ;
Daidone, MG ;
Zaffaroni, N .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (14) :1764-1774
[6]
TERT regulates cell survival independent of telomerase enzymatic activity [J].
Cao, Y ;
Li, H ;
Deb, S ;
Liu, JP .
ONCOGENE, 2002, 21 (20) :3130-3138
[7]
P53 ONCOGENE MUTATIONS IN 3 HUMAN PROSTATE-CANCER CELL-LINES [J].
CARROLL, AG ;
VOELLER, HJ ;
SUGARS, L ;
GELMANN, EP .
PROSTATE, 1993, 23 (02) :123-134
[8]
New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin [J].
Chan, SWL ;
Blackburn, EH .
ONCOGENE, 2002, 21 (04) :553-563
[9]
The hTERTα splice variant is a dominant negative inhibitor of telomerase activity [J].
Colgin, LM ;
Wilkinson, C ;
Englezou, A ;
Kilian, A ;
Robinson, MO ;
Reddel, RR .
NEOPLASIA, 2000, 2 (05) :426-432
[10]
Telomerase inhibition, oligonucleotides, and clinical trials [J].
Corey, DR .
ONCOGENE, 2002, 21 (04) :631-637